Enzo Biochem Second Quarter 2023 Earnings: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)
Enzo Biochem (NYSE:ENZ) Second Quarter 2023 Results
Key Financial Results
Revenue: US$16.3m (down 52% from 2Q 2022).
Net loss: US$11.3m (loss widened by 326% from 2Q 2022).
US$0.23 loss per share (further deteriorated from US$0.055 loss in 2Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Enzo Biochem shares are up 104% from a week ago.
Risk Analysis
We should say that we've discovered 4 warning signs for Enzo Biochem (3 don't sit too well with us!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
